CRLPartnership•businesswire•
Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences
Sentiment:Positive (70)
Summary
(NYSE:CRL) WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Integration of Akadeum’s GMP-grade Human T Cell Leukopak Isolation Kit into Charles River’s Cell Therapy Flex Program announced today
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 3, 2025 by businesswire